ArticleOncotarget2017
MAEL contributes to gastric cancer progression by promoting ILKAP degradation.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Dysregulation of piRNA biogenesis-associated proteins in cancer: mechanisms, evidence, and translational constraints.Frontiers in molecular biosciences · 2026Review
- ILKAP drives hepatocellular carcinoma progression by modulating PGAM1-mediated glycolytic reprogramming.Frontiers of medicine · 2025Article
- Article
- Inhibition ofInternational journal of molecular sciences · 2023Article
- Article
- Morphine suppresses the immune function of lung cancer by up-regulating MAEL expression.BMC pharmacology & toxicology · 2022Article
- Identification of MAEL as a promoter for the drug resistance model of iPSCs derived from T-ALL.Cancer medicine · 2022Article
- MAEL as a diagnostic marker for the early detection of esophageal squamous cell carcinoma.Diagnostic pathology · 2021Article
- Analysing a Novel RNA-Binding-Protein-Related Prognostic Signature Highly Expressed in Breast Cancer.Journal of healthcare engineering · 2021Article
- GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling.Analytical cellular pathology (Amsterdam) · 2021Article
- MAEL Cancer-Testis Antigen as a Diagnostic Marker in Primary Stages of Gastric Cancer with Helicobacter pylori Infection.Journal of gastrointestinal cancer · 2020Article
- Genome-Wide Analysis of Methylation-Driven Genes and Identification of an Eight-Gene Panel for Prognosis Prediction in Breast Cancer.Frontiers in genetics · 2020Article
- ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.Cell death & disease · 2019Article
- CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.Journal of experimental & clinical cancer research : CR · 2019Article
- Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.Trends in cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer-testis gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.